Julian Johnson, MD
Radiation Oncology · Atlanta, GANPI 1215228614
Payments from drug & device makers
What this record shows
GT Medical Technologies, Inc accounts for 70.6% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $670, more than ten times the $18 reported in 2019.
Across 13 payments — averaging $69.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GT Medical Technologies, Inc$640
- Novartis$115
- Elekta, Inc.$38
- Bard Peripheral Vascular, Inc.$33
- Bayer$27
- Hologic Sales And Service, LLC$19
- plus $34 from 2 others
Across 2 payments — averaging $8428.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$17K
What the payments were for
- Consulting fees$50055%
- Food & beverage$40745%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GT Medical Technologies, Inc | 2 | $640 |
| Novartis | 5 | $115 |
| Elekta, Inc. | 1 | $38 |
| Bard Peripheral Vascular, Inc. | 1 | $33 |
| Bayer | 1 | $27 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Coherus Oncology, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GammaTile$640
How this compares
$907 in reported general payments places this provider in the 60th percentile of 165 radiation oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mometasone Furoate | 36 | $878 |
| Tamsulosin Hcl | 37 | $401 |
| Lidocaine Hcl ViscousLidocaine Hcl | 15 | $385 |
| Oxycodone Hcl | 25 | $217 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Atlanta
- Kristin HigginsAtlanta$230K
- Walter CurranAtlanta$83K
- Ian CrockerAtlanta$51K
- Sagar PatelAtlanta$32K
- Hui-Kuo ShuAtlanta$25K
- Wilfred WilliamsAtlanta$15K
- Nancy WiggersAtlanta$11K
- Adam NowlanAtlanta$11K
- Ashesh JaniAtlanta$10K
- Frederick SchnellAtlanta$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.